CN114558002A - 化合物在制备治疗肿瘤药物中的应用 - Google Patents
化合物在制备治疗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN114558002A CN114558002A CN202210253564.0A CN202210253564A CN114558002A CN 114558002 A CN114558002 A CN 114558002A CN 202210253564 A CN202210253564 A CN 202210253564A CN 114558002 A CN114558002 A CN 114558002A
- Authority
- CN
- China
- Prior art keywords
- compound
- radical
- preparing
- medicament
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 68
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 101001015963 Homo sapiens E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract description 25
- 102000055302 human MDM2 Human genes 0.000 abstract description 25
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- -1 RG7338 Chemical compound 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DRLCSJFKKILATL-YWCVFVGNSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2s)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@](C)(CC(O)=O)C2)=O)[C@H](CS(=O)(=O)C(C)C)C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 DRLCSJFKKILATL-YWCVFVGNSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CLRSLRWKONPSRQ-IIPSPAQQSA-N C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-IIPSPAQQSA-N 0.000 description 1
- YJCZPJQGFSSFOL-MNZPCBJKSA-N CCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O Chemical compound CCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O YJCZPJQGFSSFOL-MNZPCBJKSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- IDKAKZRYYDCJDU-HBMMIIHUSA-N chembl2381408 Chemical compound C1([C@H]2[C@@H](N[C@H]([C@]22C3=CC=C(Cl)C=C3NC2=O)CC(C)(C)C)C(=O)N[C@@H]2CC[C@@H](O)CC2)=CC=CC(Cl)=C1F IDKAKZRYYDCJDU-HBMMIIHUSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种化合物在制备治疗肿瘤药物中的应用,所述化合物具有如式I~III所示的通式结构。本发明所提供的一系列具有HDM2抑制活性的化合物能够用于制备治疗肿瘤的药物,经过体外抗肿瘤活性实验,证明其有明显的人类双微体‑2(HDM2)抑制作用。
Description
技术领域
本发明涉及医药技术领域,具体涉及化合物通过抑制人类双微体-2(HDM2)活性在制备治疗肿瘤药物中的应用。
背景技术
癌症一直以不断上升的发病率和死亡率折磨着人类,目前癌症已经成为人死亡的重要原因,是一个主要的公共卫生问题。
肿瘤抑制蛋白p53通过细胞周期阻滞、DNA修复、细胞衰老和细胞凋亡等生物学功能在防止肿瘤发生中发挥核心作用。在大约一半的癌症病例中,p53因突变或缺失而失活;在许多其他癌症病例中,HDM2过表达使p53失活。HDM2是p53的主要负调控因子。在正常细胞中,HDM2和p53形成一个负反馈回路,将p53和HDM2维持在非常低的水平。因此,HDM2被认为是p53的有效抑制剂。当HDM2在人类肿瘤中通过基因扩增、转录水平升高和翻译增强而异常上调时,HDM2的过表达会损害p53的稳定性和活性,具有致癌作用,在人类肿瘤中HDM2扩增的频率为7%。因此,将HDM2作为药物靶点,发现抑制剂可以抑制HDM2从而恢复p53的活性,达到抗肿瘤的作用。
至今为止,药物化学家已经报道了很多种HDM2-p53蛋白相互作用的抑制剂,在临床试验的药物有RG7112、RG7338、SAR405838、HDM201、AMG-232和CGM097,国内除了药物APG-115进入临床试验阶段,还没有其他相关的研究进展报道,目前HDM2抑制剂的活性和生物利用度仍然有限,还未有上市的临床药物,而且,HDM2小分子抑制剂主要骨架为顺式咪唑啉(Nutlin)类骨架,新型骨架较少,缺乏多样性。
发明内容
针对现有技术存在的上述不足,本发明的目的在于提供一种化合物在制备治疗肿瘤药物中的应用,以解决现有技术中HDM2-p53蛋白相互作用的抑制剂活性和生物利用度仍然有限的问题。
为了解决上述技术问题,本发明采用如下技术方案:
一种化合物在制备治疗肿瘤药物中的应用,所述化合物的结构式如下:
优选为,所述化合物的结构式如下所示:
一种化合物在制备治疗肿瘤药物中的应用,所述化合物的结构式如下:
优选为,所述化合物的结构式如下所示:
一种化合物在制备治疗肿瘤药物中的应用,所述化合物的结构式如下:
优选为,所述化合物的结构式如下所示:
优选为,所述赋形剂包括填充剂、粘合剂、崩解剂、润滑剂或助流剂中的一种或多种;所述填充剂包括淀粉、糖粉、微晶纤维素、甘露醇或乳糖;所述粘合剂包括淀粉浆、羟丙基纤维素、甲基纤维素、乙基纤维素、聚乙烯吡咯烷酮或羧甲基纤维素钠;所述崩解剂包含羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、交联聚乙烯吡咯烷酮或羟丙基淀粉;所述润滑剂为硬脂酸镁;所述助流剂为滑石粉。其中,粘合剂为0.1-15%的羟丙基纤维素,填充剂为5-70%的微晶纤维素,崩解剂为10-60%的交联聚维酮;所述润滑剂为0.1-5%的硬脂酸镁;所述助流剂为0.1-3%的滑石粉。
优选为,所述药物组合物的剂型包括片剂、胶囊剂、丸剂或混悬剂。
与现有技术相比,本发明具有如下有益效果:
本发明提供了如式Ⅰ、Ⅱ、Ⅲ所示的化合物在抑制人类双微体-2活性中的应用及治疗抗肿瘤药物组合物,通过体外的抗肿瘤活性实验,证明其具有明显的人类双微体-2(HDM2)抑制作用,且与目前的药物相比较,本发明提供的这类化合物对人体无毒副作用,对人类双微体-2具有较强的抑制作用。
具体实施方式
下面将结合实施例对本发明作进一步说明。
一、目标化合物的来源
本发明所有化合物均购买于荷兰specs公司(网址:http://www.specs.com,均为specs公司化合物库中的化合物,相应的编号如下:
表1:本发明化合物的编号及结构
二、本发明化合物的体外药理学测试
2.1实验原理
MTS为一种全新的MTT类似物,是一种黄颜色的染料,其英文全称为3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium。活细胞线粒体中琥珀酸脱氢酶能够代谢还原MTS,生成可溶性的甲臜(Formazan)化合物,甲臜的含量可以用酶标仪在490nm处进行测定。在通常情况下,甲臜生成量与活细胞数成正比,因此可根据光密度OD值推测出活细胞的数目。
2.2实验方法
1.接种细胞:用含10%胎牛血清的RMPI1640培养液配成单个细胞悬液,以每孔5000个细胞接种到96孔板,每孔体积100μl,细胞提前12~24小时接种培养。
2.加入待测化合物溶液:化合物用DMSO溶解,化合物以40μM、8μM、1.6μM、0.32μM、0.064μM浓度复筛,每孔终体积200μl,每种处理均设3个复孔。
3.显色:37摄氏度培养48小时后,贴壁细胞弃孔内培养液,每孔加MTS溶液20μl和培养液100μl;设3个空白复孔(MTS溶液20μl和培养液100μl的混合液),继续孵育2~4小时,使反应充分进行后测定光吸收值。
4.比色:选择492nm波长,多功能酶标仪(MULTISKAN FC)读取各孔光吸收值,记录结果,数据处理后以浓度为横坐标,细胞存活率为纵坐标绘制细胞生长曲线,应用两点法(Reed and Muench法)计算化合物的IC50值。
5.阳性对照化合物:每次实验均设顺铂(DDP)和紫杉醇(Taxol)两个阳性化合物,以浓度为横坐标,细胞存活率为纵坐标绘制细胞生长曲线,应用两点法(Reed and Muench法)计算化合物的IC50值。
2.3实验结果
1)化合物对人类双微体-2(HDM2)的抑制作用
抑制率(%)可通过样品组及空白组A值的变化,用下列公式计算:抑制率(%)=(1-A样品/A空白)×100%,抑制率结果见下表:
表2:化合物对人类双微体-2(HDM2)的抑制率
化合物 | 抑制率(样品浓度为25μM) |
CF-1 | 6.1% |
CF-2 | 7.2% |
CF-3 | 60.2% |
CF-4 | 9.2% |
从表2可以看出,化合物CF-3对人类双微体-2(HDM2)表现出较高的抑制率。
2)化合物对肝癌SMMC-7721的抑制活性IC50的测定
通过实验测定了化合物对肝癌SMMC-7721的抑制活性IC50的值,具体实验过程同上,结果见表3。
表3:化合物对肝癌SMMC-7721的IC50(μM)
化合物 | IC<sub>50</sub>±SD(μM) |
CF-1 | >40 |
CF-2 | >40 |
CF-3 | 14.14±0.80 |
CF-4 | >40 |
顺铂(阳性对照) | 15.16±1.13 |
紫杉醇(阳性对照) | 0.466±0.025 |
三、本发明化合物及其在药学上可接受的盐、水合物或溶剂化物的药物组合物
(1)按照下述配方将药物组合物制成片剂
表4
制法:本法采用干法制粒压片。依次将本发明化合物与微晶纤维素、羟丙甲基纤维素及内加量的交联聚维酮混合,过80目筛三次,干法制粒机制粒,整粒后于80℃干燥,水分小于3%。干燥后的颗粒再加入外加量的交联聚维酮、硬脂酸镁和滑石粉,混合均匀后,压片,包薄膜衣即得。
(2)按照下述配方将药物组合物制成胶囊剂
表5
名称 | 质量/g | 百分比/% | 作用 |
本发明化合物 | 12 | 12% | 主药 |
微晶纤维素 | 40 | 40% | 填充剂 |
乳糖 | 30 | 30% | 填充剂 |
低取代羟丙基纤维素 | 7 | 7% | 粘合剂 |
硬脂酸镁 | 2 | 2% | 润滑剂 |
滑石粉 | 1 | 1% | 助流剂 |
制法:将本发明化合物与上述辅料混合,过60目筛,制粒,干燥,整粒,填装胶囊即得。
最后需要说明的是,以上实施例仅用以说明本发明的技术方案而非限制技术方案,本领域的普通技术人员应当理解,那些对本发明的技术方案进行修改或者等同替换,而不脱离本技术方案的宗旨和范围,均应涵盖在本发明的权利要求范围当中。
Claims (9)
7.根据权利要求1~6任一所述化合物在制备治疗肿瘤药物中的应用,其特征在于,以100份重量份计,包含12~20份所述的化合物,或者该化合物在药学上可接受的盐、水合物或溶剂化物,余量为赋形剂。
8.根据权利要求7所述化合物在制备治疗肿瘤药物中的应用,其特征在于,所述赋形剂包括填充剂、粘合剂、崩解剂、润滑剂或助流剂中的一种或多种;所述填充剂包括淀粉、糖粉、微晶纤维素、甘露醇或乳糖;所述粘合剂包括淀粉浆、羟丙基纤维素、甲基纤维素、乙基纤维素、聚乙烯吡咯烷酮或羧甲基纤维素钠;所述崩解剂包含羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、交联聚乙烯吡咯烷酮或羟丙基淀粉;所述润滑剂为硬脂酸镁;所述助流剂为滑石粉。
9.根据权利要求1~6任一所述化合物在制备治疗肿瘤药物中的应用,其特征在于,所述药物组合物的剂型包括片剂、胶囊剂、丸剂或混悬剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210253564.0A CN114558002A (zh) | 2022-03-15 | 2022-03-15 | 化合物在制备治疗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210253564.0A CN114558002A (zh) | 2022-03-15 | 2022-03-15 | 化合物在制备治疗肿瘤药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114558002A true CN114558002A (zh) | 2022-05-31 |
Family
ID=81719679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210253564.0A Pending CN114558002A (zh) | 2022-03-15 | 2022-03-15 | 化合物在制备治疗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114558002A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019594A1 (en) * | 1991-05-02 | 1992-11-12 | Smithkline Beecham Corporation | Pyrrolidinones |
US20090324708A1 (en) * | 2006-11-06 | 2009-12-31 | Universidad Nacional De Quilmes | Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprising thereof and a method for the treatment of rho-gtpase cell protein-mediated condition |
CN102149708A (zh) * | 2008-09-15 | 2011-08-10 | 普里阿克索股份公司 | 作为hdm2配体的吡咯烷-2-酮 |
CN103142584A (zh) * | 2013-02-21 | 2013-06-12 | 中国农业大学 | 多取代5-羟基吡咯酮类化合物在制备抗肿瘤的药物中的应用 |
CN107362166A (zh) * | 2017-08-01 | 2017-11-21 | 中国科学院昆明植物研究所 | 四氢吡啶并[4,5‑]噻吩并[2,3‑]嘧啶‑4(3)‑酮类化合物在制药中的应用 |
CN108653282A (zh) * | 2018-06-28 | 2018-10-16 | 中国科学院昆明植物研究所 | 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用 |
KR20190014370A (ko) * | 2017-08-02 | 2019-02-12 | 재단법인 한국파스퇴르연구소 | 신규 이미노디피리디노피리미딘 유사체, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 c형 간염 바이러스에 대한 항바이러스 조성물 |
-
2022
- 2022-03-15 CN CN202210253564.0A patent/CN114558002A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019594A1 (en) * | 1991-05-02 | 1992-11-12 | Smithkline Beecham Corporation | Pyrrolidinones |
US20090324708A1 (en) * | 2006-11-06 | 2009-12-31 | Universidad Nacional De Quilmes | Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprising thereof and a method for the treatment of rho-gtpase cell protein-mediated condition |
CN102149708A (zh) * | 2008-09-15 | 2011-08-10 | 普里阿克索股份公司 | 作为hdm2配体的吡咯烷-2-酮 |
CN103142584A (zh) * | 2013-02-21 | 2013-06-12 | 中国农业大学 | 多取代5-羟基吡咯酮类化合物在制备抗肿瘤的药物中的应用 |
CN107362166A (zh) * | 2017-08-01 | 2017-11-21 | 中国科学院昆明植物研究所 | 四氢吡啶并[4,5‑]噻吩并[2,3‑]嘧啶‑4(3)‑酮类化合物在制药中的应用 |
KR20190014370A (ko) * | 2017-08-02 | 2019-02-12 | 재단법인 한국파스퇴르연구소 | 신규 이미노디피리디노피리미딘 유사체, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 c형 간염 바이러스에 대한 항바이러스 조성물 |
CN108653282A (zh) * | 2018-06-28 | 2018-10-16 | 中国科学院昆明植物研究所 | 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用 |
Non-Patent Citations (4)
Title |
---|
SERGEY V,等: "Approach to the Library of 3‑Hydroxy-1,5-dihydro‑2H‑pyrrol-2-ones through a Three-Component Condensation", ACS COMBINATORIAL SCIENCE * |
XI JIANG,等: "A Series of Compounds Bearing a Dipyrido-Pyrimidine Scaffold Acting as Novel Human and Insect Pest Chitinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY * |
冉义江,等: "吡咯啉类化合物的生物活性研究进展", 化工管理 * |
吴林韬,等: "吡啶并[2,3-d]嘧啶类衍生物的多组分反应合成机理及抗肿瘤活性", 扬州大学学报(自然科学版) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230190732A1 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
CN104758265B (zh) | 一种雷诺嗪缓释片药物组合物及其制备方法 | |
CN111297867A (zh) | 含有吡啶基氨基吡啶并嘧啶衍生物的组合物在制备用于治疗乳腺癌的药物中的用途 | |
CN107334767B (zh) | 一种哒嗪酮类化合物在肿瘤治疗中的应用 | |
CN114558002A (zh) | 化合物在制备治疗肿瘤药物中的应用 | |
CN110833529A (zh) | 一种盐酸特比萘芬片及其制备方法 | |
CN112402388A (zh) | 一种用于治疗膀胱癌的口服固体制剂及其制备方法 | |
CN112552287B (zh) | 一种吲哚类衍生物药物制剂及其制备方法 | |
CN111803499B (zh) | 一种治疗抗痛风、抗高尿酸血症的药物组合物ⅱ | |
EP4122480A1 (en) | Use of astragalus medicinal composition for preparing drug for enhancing cancer therapy | |
CN108403661B (zh) | 一种治疗非小细胞肺癌的药物微囊制剂及其制备方法 | |
CN114869893A (zh) | 一种药物组合物及其应用 | |
CN114028400A (zh) | 一种含有细胞周期蛋白激酶抑制剂的药物组合物及其制备方法 | |
CN112675171B (zh) | 抑制vegfr活性化合物药物制剂及其制备方法 | |
CN105001167A (zh) | 1-取代苯基-3-(4-取代苯基氨基-6-喹唑啉基)脲类化合物及制备方法和用途 | |
CN113648291B (zh) | 苯丁烯酮化合物在制备肺癌化疗增敏药物中的应用及药物 | |
CN110590778A (zh) | 3,10二对甲氧基苯基6,12二氮杂四高立方烷类化合物及合成方法应用和药物组合物 | |
CN111646956B (zh) | 一种哌嗪基取代的二苯基亚砜类化合物及其组合物和应用 | |
CN109350620B (zh) | 一种治疗卵巢癌的药物及其用途 | |
CN103304556B (zh) | 含有苯并吡喃的希夫碱类化合物、其制备方法和用途 | |
CN113321631B (zh) | 双穿心莲内酯g及其制备方法和在药物上的应用 | |
CN112438978B (zh) | 一种西达本胺药物组合物及其制备方法和应用 | |
CN110938025B (zh) | 一种儿茶醛缩苯基氨基硫脲化合物在防治痛风和高尿酸血症中的应用 | |
CN102276625B (zh) | 噻二唑衍生物 | |
CN108969520A (zh) | 一种n-甲基甲胺盐酸盐的a晶型化合物的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220531 |